Literature DB >> 10470708

Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis.

J N Boletis, J P Ioannidis, K A Boki, H M Moutsopoulos.   

Abstract

Among 14 randomised patients with proliferative lupus nephritis, monthly intravenous immunoglobulin maintained remission over 18 months, similar to standard intravenous cyclophosphamide treatment. Pulsed immunoglobulin may be a useful alternative therapy in lupus nephritis.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10470708     DOI： 10.1016/S0140-6736(99)01575-5

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  30 in total

Review 1.  Immunomodulation of autoimmune diseases by high-dose intravenous immunoglobulins.

Authors:  L Rauova; J Rovensky; Y Shoenfeld
Journal:  Springer Semin Immunopathol       Date:  2001-12

Review 2.  Clinical trials in lupus nephritis.

Authors:  E M Ginzler
Journal:  Curr Rheumatol Rep       Date:  2001-06       Impact factor: 4.592

Review 3.  Treatment of severe proliferative lupus nephritis: the current state.

Authors:  C C Mok; R W S Wong; K N Lai
Journal:  Ann Rheum Dis       Date:  2003-09       Impact factor: 19.103

Review 4.  Intravenous immunoglobulin therapy and systemic lupus erythematosus.

Authors:  Gisele Zandman-Goddard; Yair Levy; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 5.  Clinical uses of intravenous immunoglobulin.

Authors:  S Jolles; W A C Sewell; S A Misbah
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

Review 6.  Intravenous immunoglobulin: an update on the clinical use and mechanisms of action.

Authors:  Vir-Singh Negi; Sriramulu Elluru; Sophie Sibéril; Stéphanie Graff-Dubois; Luc Mouthon; Michel D Kazatchkine; Sébastien Lacroix-Desmazes; Jagadeesh Bayry; Srini V Kaveri
Journal:  J Clin Immunol       Date:  2007-03-11       Impact factor: 8.317

Review 7.  Recent advances on pathogenesis and therapies in systemic sclerosis.

Authors:  Norihito Yazawa; Manabu Fujimoto; Kunihiko Tamaki
Journal:  Clin Rev Allergy Immunol       Date:  2007-10       Impact factor: 8.667

Review 8.  Intravenous immunoglobulin in neurological disease: a specialist review.

Authors:  C M Wiles; P Brown; H Chapel; R Guerrini; R A C Hughes; T D Martin; P McCrone; J Newsom-Davis; J Palace; J H Rees; M R Rose; N Scolding; A D B Webster
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-04       Impact factor: 10.154

Review 9.  Current concepts for the management of systemic lupus erythematosus in adults: a therapeutic challenge.

Authors:  Y Ioannou; D A Isenberg
Journal:  Postgrad Med J       Date:  2002-10       Impact factor: 2.401

Review 10.  Treatment of lupus nephritis.

Authors:  Fayez F Hejaili; Louise M Moist; William F Clark
Journal:  Drugs       Date:  2003       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.